The protective effects of ursodeoxycholic acid and the selective cyclooxygenase-2 inhibitor celecoxib on liver damage in an experimental cholestasis model

• Published in: Experimental biomedical research Vol. 2; no. 2; pp. 50 - 61
• Main Authors: Ozturk, Hulya, Kucuk, Adem
• Format: Journal Article
• Language: English
• Published: Bolu Prof. Dr. Hayrettin Öztürk 01.04.2019; Experimental Biomedical Research
• Subjects: Bile; Bile ducts; Celecoxib; Cell death; Cholestasis; Cirrhosis; Cyclooxygenase-2; Dietary supplements; Fibrosis; Gallbladder diseases; Hepatocytes; Inflammation; Liver; Liver cirrhosis; Liver diseases; Sağlık Hizmetleri; Tıp; Ursodeoxycholic acid; Bolu; Türkiye; ursodeoxycholic acid; hepatic fibrosis; celecoxib; Cholestasis; cyclooxygenase-2

Aim: Cholestasis leads to liver cell death, fibrosis, cirrhosis, and eventually liver failure. Ursodeoxycholic acid (UDCA) is the only Food and Drug Administration-approved treatment for cholestatic disorders. Hepatic cyclooxygenase-2 (COX-2) expression increases in various chronic liver diseases ca...